Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva to acquire ratiopharm

This article was originally published in The Tan Sheet

Executive Summary

Teva Pharmaceutical Industries' nearly $5 billion (€3.6 billion) pending acquisition of Germany's second-largest generics manufacturer ratiopharm catapults the Israeli company to second place in Germany's generic market. The deal also gives Teva an OTC platform in Germany, which could help the firm gain favor with pharmacists. In Germany, firms can offer pharmacists incentives for choosing specific OTC products, but not for generics. Ratiopharm sells approximately 20 percent non-prescription drugs, including cold and flu remedies, plant-derived medicines and health supplements, according to its Web site. Teva expects the mostly cash deal to be accretive nine months after it closes
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS103928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel